BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 18636202)

  • 1. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
    Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
    Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
    Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
    Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
    Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation.
    Fontana RJ; Hamidullah H; Nghiem H; Greenson JK; Hussain H; Marrero J; Rudich S; McClure LA; Arenas J
    Liver Transpl; 2002 Dec; 8(12):1165-74. PubMed ID: 12474157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.
    Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Minami Y; Ueshima K; Haji S
    Oncology; 2007; 72 Suppl 1():98-103. PubMed ID: 18087189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
    Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
    Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis.
    Raut CP; Izzo F; Marra P; Ellis LM; Vauthey JN; Cremona F; Vallone P; Mastro A; Fornage BD; Curley SA
    Ann Surg Oncol; 2005 Aug; 12(8):616-28. PubMed ID: 15965731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is percutaneous radiofrequency thermal ablation of hepatocellular carcinoma a safe procedure?
    Zavaglia C; Corso R; Rampoldi A; Vinci M; Belli LS; Vangeli M; Solcia M; Castoldi C; Prisco C; Vanzulli A; Pinzello G
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):196-201. PubMed ID: 18301300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.
    Kobayashi M; Ikeda K; Kawamura Y; Yatsuji H; Hosaka T; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Kumada H
    Cancer; 2009 Feb; 115(3):571-80. PubMed ID: 19117347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome.
    Zytoon AA; Ishii H; Murakami K; El-Kholy MR; Furuse J; El-Dorry A; El-Malah A
    Jpn J Clin Oncol; 2007 Sep; 37(9):658-72. PubMed ID: 17766723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence.
    Pompili M; Mirante VG; Rondinara G; Fassati LR; Piscaglia F; Agnes S; Covino M; Ravaioli M; Fagiuoli S; Gasbarrini G; Rapaccini GL
    Liver Transpl; 2005 Sep; 11(9):1117-26. PubMed ID: 16123960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiofrequency ablation after transarterial embolization as therapy for patients with unresectable hepatocellular carcinoma.
    Liao GS; Yu CY; Shih ML; Chan DC; Liu YC; Yu JC; Chen TW; Hsieh CB
    Eur J Surg Oncol; 2008 Jan; 34(1):61-6. PubMed ID: 17434711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class a liver cirrhosis.
    Santambrogio R; Opocher E; Zuin M; Selmi C; Bertolini E; Costa M; Conti M; Montorsi M
    Ann Surg Oncol; 2009 Dec; 16(12):3289-98. PubMed ID: 19727960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
    Prete SD; Montella L; Caraglia M; Maiorino L; Cennamo G; Montesarchio V; Piai G; Febbraro A; Tarantino L; Capasso E; Palmieri G; Guarrasi R; Bianco M; Mamone R; Savastano C; Pisano A; Vincenzi B; Sabia A; D'Agostino A; Faiola V; Addeo R
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):837-44. PubMed ID: 20041325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
    Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
    Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined ethanol injection therapy and radiofrequency ablation therapy in percutaneous treatment of hepatocellular carcinoma larger than 4 cm.
    Vallone P; Catalano O; Izzo F; Siani A
    Cardiovasc Intervent Radiol; 2006; 29(4):544-51. PubMed ID: 16528626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiofrequency ablation for unresectable tumors of the liver.
    Howard JH; Tzeng CW; Smith JK; Eckhoff DE; Bynon JS; Wang T; Arnoletti JP; Heslin MJ
    Am Surg; 2008 Jul; 74(7):594-600; discussion 600-1. PubMed ID: 18646476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The factors related to the prognosis of solitary hepatocellular carcinoma after radiofrequency ablation].
    Chung IK; Park MJ; Kwon KT; Park YD; Chung YJ; Jeon SW; Lee MK; Seo HE; Lee YD; Cho CM; Tak WY; Kweon YO; Kim SK; Choi YH
    Korean J Hepatol; 2005 Dec; 11(4):371-80. PubMed ID: 16380666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation.
    Takahashi S; Kudo M; Chung H; Inoue T; Nagashima M; Kitai S; Tatsumi C; Minami Y; Ueshima K; Fukunaga T; Haji S
    Dig Dis; 2007; 25(4):303-9. PubMed ID: 17960064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy].
    Hirashita T; Nakashima K; Sakai M; Sakai I
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1123-6. PubMed ID: 17637554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.